Your browser doesn't support javascript.
loading
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with lymphoid malignancies
Sean Hua Lim; Nicola Campbell; Beth Stuart; Marina Johnson; Debora Joseph-Pietras; Adam Kelly; Danielle Jeffrey; Anna H Turaj; Kate Rolfvondenbaumen; Celine Galloway; Thomas Wynn; Adam R Coleman; Ben Ward; Karen Long; Andrew T Bates; Diana Ayres; Robert Lown; Janlyn Falconer; Oliver Brake; James Batchelor; Victoria Willimott; Anna Bowzyk Al-Naeeb; Lisa Robinson; Ann O'Callaghan; Graham P Collins; Tobias Menne; Saul Faust; Christopher P Fox; Matthew Ahearne; Peter W.M. Johnson; Andrew J Davies; David Goldblatt.
Afiliación
  • Sean Hua Lim; University of Southampton
  • Nicola Campbell; University Hospital Southampton NHS Foundation Trust
  • Beth Stuart; Southampton Clinical Trials Unit, University of Southampton
  • Marina Johnson; Great Ormond Street Institute Of Child Health Biomedical Research Centre, University College London
  • Debora Joseph-Pietras; NIHR/Cancer Research UK Southampton Experimental Cancer Medicine Centre, WISH Laboratory
  • Adam Kelly; NIHR/Cancer Research UK Southampton Experimental Cancer Medicine Centre, WISH Laboratory
  • Danielle Jeffrey; NIHR/Cancer Research UK Southampton Experimental Cancer Medicine Centre, WISH Laboratory
  • Anna H Turaj; University of Southampton
  • Kate Rolfvondenbaumen; NIHR/Cancer Research UK Southampton Experimental Cancer Medicine Centre, WISH Laboratory
  • Celine Galloway; NIHR/Cancer Research UK Southampton Experimental Cancer Medicine Centre, WISH Laboratory
  • Thomas Wynn; NIHR/Cancer Research UK Southampton Experimental Cancer Medicine Centre, WISH Laboratory
  • Adam R Coleman; NIHR/Cancer Research UK Southampton Experimental Cancer Medicine Centre, WISH Laboratory
  • Ben Ward; NIHR/Cancer Research UK Southampton Experimental Cancer Medicine Centre, WISH Laboratory
  • Karen Long; University of Southampton Clinical Informatics Research Unit
  • Andrew T Bates; University Hospital Southampton NHS Foundation Trust
  • Diana Ayres; University Hospital Southampton NHS Foundation Trust
  • Robert Lown; University Hospital Southampton NHS Foundation Trust
  • Janlyn Falconer; University Hospital Southampton NHS Foundation Trust
  • Oliver Brake; University Hospital Southampton NHS Foundation Trust
  • James Batchelor; University of Southampton Clinical Informatic Research Unit
  • Victoria Willimott; Norfolk and Norwich University Hospital NHS Foundation Trust
  • Anna Bowzyk Al-Naeeb; Bedford Hospital
  • Lisa Robinson; County Hospital Hereford
  • Ann O'Callaghan; Portsmouth Hospitals NHS Foundation Trust
  • Graham P Collins; Oxford University Hospitals NHS Foundation Trust
  • Tobias Menne; Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Saul Faust; NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre
  • Christopher P Fox; Nottingham University Hospital NHS Trust
  • Matthew Ahearne; University Hospitals Leicester NHS Trust
  • Peter W.M. Johnson; University of Southampton
  • Andrew J Davies; University of Southampton
  • David Goldblatt; Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21266760
ABSTRACT
SARS-CoV-2 vaccination protects against COVID-19. Antibodies and antigen-specific T-cell responses against the spike domain can be used to measure vaccine immune response. Individuals with lymphoma have defects in humoral and cellular immunity that may compromise vaccine response. In this prospective observational study of 457 participants with lymphoma, 52% of participants vaccinated on treatment had undetectable anti-spike IgG antibodies compared to 9% who were not on treatment. Marked impairment was observed in those receiving anti- CD20 antibody within 12 months where 60% had undetectable antibodies compared to 11% on chemotherapy, which persisted despite three vaccine doses. Overall, 63% had positive T-cell responses irrespective of treatment. Individuals with indolent B-cell lymphoma have impaired antibody and cellular responses that were independent of treatment. The significant reduction and heterogeneity in immune responses in these individuals emphasise the urgent need for immune response monitoring and alternative prophylactic strategies to protect against COVID- 19.
Licencia
cc_no
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint